Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has renewed two agreements to continue leasing certain property and assets from controlling shareholder Kelun Pharmaceutical for the three years ending Dec. 31, 2027, a Jan. 28 bourse filing said.
The leased properties in Chengdu, China, are being used by the company for its daily operations, such as for R&D activities, and as a storage house, office space, and staff housing solution.
The equipment comprises around 1,074 pieces of equipment including manufacturing and laboratory equipment and instruments.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。